AZITHROMYCIN-AFT (AFT Pharmaceuticals Pty Ltd)
Product name
AZITHROMYCIN-AFT
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
251 working days (255)
Active ingredients
azithromycin
Registration type
New generic medicine
Indication
AZITHROMYCIN-AFT (powder for injection) is indicated for the treatment of community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. In clinical studies efficacy has been demonstrated against Chlamydia pneumoniae, Haemophilus influenzae, Legionella pneumophilia, Moraxella catarrhalis, Mycoplasma pneumoniae, Staphylococcus aureus and Streptococcus pneumoniae.